(NASDAQ:IMMU) has "Hold" rating given on Wednesday, July 29 by Jefferies. Approximately 31.2% of the shares of the stock are short sold. Wells Fargo downgraded the shares of IMMU in report on Tuesday, June 21 to "Market Perform" …
NASDAQ
Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $5 highest and $1.50 lowest target. $10's average target is 30.89% above currents $7.64 …
Optimism
Research analysts at Jefferies Group lowered their FY2017 earnings per share estimates for Immunomedics in a note issued to investors on Monday. Equities research analysts predict that Immunomedics will post ($0.70) EPS for the …
Stock Price
Css Llc acquired 197,800 shares as Immunomedics Inc (Put) (IMMU)'s stock
Dow Chemical
The 52-week range for the shares is $45.28 to $62.64. The stock closed trading Thursday at $62.58. Other key analysts …
Analyst Upgrades
Jefferies upgraded Immunomedics, Inc. (IMMU) is at 61.4. (IMMU) stock showed the move of 17.56% with the closing price of $6.36. This is the price at which the trader or investor wants to exit his existing position so he can realize the most …
Analyst Ratings
Immunomedics, Inc. (NASDAQ: IMMU) is having an overwhelmingly strong day in the market, and for good reason. The company made a key business update that led to excitement among investors. Of course, our partners at Trade Ideas …
Gain
Eikon search string for individual stock moves: [STXBZ] * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were little changed in late morning trading on …
NASDAQ
As part of Venbio takeover, Immunomedics exits licensing deal with Seattle Genetics and raises 125 million in cash with private placement of preferred stock. Immunomedics (NASDAQ:IMMU) "is committed to be a leading, innovative …
Seeking Alpha
News articles about Immunomedics (NASDAQ:IMMU) have been trending positive this week, AlphaOne reports. The research group, a division of Accern, identifies positive and negative press coverage by reviewing more than 20 million …
BNS16d